MIRM - NASDAQ
Mirum Pharmaceuticals, Inc.
$91.83
-0.016%Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
At a Glance
Live SnapshotMirum Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Mirum Pharmaceuticals, Inc. Income Statement
MIRM • NASDAQ
| Mirum Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
521.3M | 336.9M | 186.4M | 77.1M | 19.1M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(100.6M) | (81.6M) | (47M) | (12.4M) | (1.9M) | (623K) | (324K) | (0.0) | |
420.7M | 255.2M | 139.3M | 64.7M | 17.2M | -623K | -324K | 0.0 | |
OPERATING INCOME | ||||||||
(443.2M) | (342.9M) | (248.5M) | (195.9M) | (190.6M) | (103.7M) | (54.7M) | (2.9M) | |
(257M) | (202.2M) | (145.9M) | (89.1M) | (59.2M) | (22.7M) | (11.8M) | (585K) | |
(186.2M) | (140.6M) | (102.6M) | (106.8M) | (131.4M) | (81.6M) | (43M) | (2.3M) | |
-22.1M | -87.6M | -109.2M | -131.2M | -173.4M | -104.3M | -54.7M | -2.9M | |
PRE-TAX INCOME | ||||||||
(14.4M) | (14.3M) | (15.1M) | (16M) | (17.6M) | (335K) | (0.0) | (0.0) | |
-1.7M | -519K | -1.4M | -12.1M | -17.2M | 1.2M | 2.2M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -623K | -21K | (0.0) | |
709K | 694K | -53.3M | -10.9M | 89.5M | 1M | 2.2M | -14.4M | |
-21.4M | -86.9M | -162.4M | -142.1M | -84M | -103.3M | -52.5M | -17.3M | |
NET INCOME | ||||||||
(1.9M) | (1M) | (991K) | -6.4M | (37K) | (6K) | (21K) | (0.0) | |
-23.4M | -87.9M | -163.4M | -135.7M | -84M | -103.3M | -52.6M | -17.3M |
SEC Filings
MIRM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
8-K/A 8-K/A 2026 (Amended) N/A | April 08, 2026 | January 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 25, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 25, 2026 | February 25, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 26, 2026 | January 23, 2026 | 2026 |
Related Guides
Continue your MIRM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.